Introduction {#sec1-1}
============

Parkinson\'s disease (PD) is a multi-system degenerative disorder, involving not only the nigral dopaminergic cells but also other predisposed nerve cells, *i.e*., non-dopaminergic structures of the lower brainstem or in the olfactory bulb (Braak et al., 2002; Burn and Tröster, 2004; Katzenschlager, 2014). Progressive degeneration of substantia nigra dopaminergic neurons leads to a subsequent loss of dopaminergic terminals in the caudate-putamen and the clinical symptoms, such as akinesia, resting tremor, muscle rigidity, and postural imbalance (Lotharius and Brundin, 2002; de la Fuente-Fernández et al., 2004).

Neurotrophic factors are important for the development and maintenance of the nervous system (Airaksinen and Saarma, 2002; Zihlmann et al., 2005; Wanigasekara and Keast, 2006). Neurturin supports the survival of ventral midbrain dopaminergic and motor neurons and induces neurite out-growth in the spinal cord (Bespalov et al., 2011; Wang et al., 2014). Glial cell line-derived neurotrophic factor (GDNF) maintains the survival and function of midbrain dopaminergic neurons *in vitro* and attenuates neuronal damage induced by 6-hydroxydopamine (6-OHDA) (Zhao et al., 2014).

The physiological functions of Persephin protein (PSPN) remain unclear at present. PSPN shares some neurotrophic effects previously described for GDNF and neurturin (Sidorova et al., 2010). It supports the survival of motor neurons cultured *in vivo* after sciatic nerve axotomy (Yang et al., 2007). However, because of the extremely low expression levels of PSPN, tissue distribution has been studied by reverse transcription-PCR only. Low PSPN mRNA expression level is found throughout the embryonic and adult central nervous system and in all peripheral tissues examined (including heart, kidney, liver, skin, and muscle) (Akerud et al., 2002).

Previous studies showed that neural stem cells modified using GDNF could survive longer than unmodified neural stem cells after intracerebral transplantation in a rat model of middle cerebral artery occlusion (Kameda et al., 2007). In the present study, we investigated whether lentivirus (LV)-mediated PSPN over-expression could enhance the survival of dopaminergic neurons in the 6-OHDA-induced PD rat model.

Materials and Methods {#sec1-2}
=====================

6-OHDA injury and LV-PSPN intervention {#sec2-1}
--------------------------------------

Forty healthy, clean, 8-month-old male Wistar rats, weighing 200--250 g, were provided by the Animal Center of Qingdao Food and Drug Administration (license No. D20131004; Qingdao, Shandong Province, China). All rats were housed in a temperature-controlled room, under a 12-hour day/night cycle, allowing free access to water and food. All experimental procedures were in accordance with the National Institute of Health Guide for Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of Qingdao University in China.

Rats adapted to the experiment conditions for 1 week before the experiment and were randomly divided into four groups. Normal group: rats were free of any treatment; 6-OHDA group: rats were injected with 6-OHDA (Sigma, St. Louis, MO, USA; dissolved to normal saline containing 0.2% ascorbic acid, 4 mg/mL) into the anterior medial bundle of the right forebrain. The coordinates of the two injection sites were: (1) 4.4 mm posterior to the bregma, 1.2 mm lateral to the median line and 7.8 mm below the dura mater; (2) 4.0 mm posterior to the bregma, 0.8 mm lateral to the median line and 8.0 mm below the dura mater. The injection volume was 2.25 µL and 2.7 µL, respectively (He et al., 2014). 6-OHDA + LV-null group: rats were first injected with 1 µL of LV only (titer 1 × 10^8^, Shanghai Genechem, Shanghai, China) on the right substantia nigra (coordinates: 5.3 mm posterior to the bregma, 1.9 mm lateral to the median line and 7.5 mm below the skull), and then injected with 6-OHDA as above 1 week later; 6-OHDA + LV-PSPN group: rats were first injected with LV-PSPN lentivirus (titer 1 × 10^8^, Shanghai Genechem) on the right substantia nigra, and then injected with 6-OHDA as above 1 week later (He et al., 2014).

Behavioral testing {#sec2-2}
------------------

After 21 days of 6-OHDA injection, subcutaneous injections with 0.05 mg/kg apomorphine (Sigma; dissolved to normal saline containing 0.2% ascorbic acid) were applied to the napes of the rats to induce the rotating behaviors of rats. The number of rotations within 30 minutes was recorded.

Immunofluorescence test {#sec2-3}
-----------------------

At 21 days after the 6-OHDA injection, rats were anesthetized with 8% chloral hydrate *via* intraperitoneal injection. A needle was inserted into the aortic ventricle of rats, and 400 mL of 37°C normal saline was infused rapidly until the liver turned white, then 4% pre-cooled paraformaldehyde was infused until the whole body of the rat became stiff. The brains were harvested and fixed in 4% paraformaldehyde for 4 hours and then hydrated in a 4°C 20% sucrose phosphate solution until the brains sank to the bottom of the centrifugation tube. Then the brains were hydrated in a 4°C 30% sucrose phosphate solution until the brains sank to the bottom of the centrifugation tube. Tissues were cut into coronal frozen sections at 20 µm thickness for immunofluorescence staining. The sections were placed in 24-well culture plates and incubated with 400 µL of mouse anti-rat TH monoclonal antibody (1:2,000; Sigma). The culture plates were then transferred to 4°C refrigerators overnight, and rinsed with PBS three times, for 10 minutes each. Then the sections were incubated with DyLight 488-labeled donkey anti-mouse IgG (1:500; Sigma) for 1 hour at room temperature, and rinsed with PBS three times, for 10 minutes each. Finally, the sections were mounted with 70% glycerol and observed under the microscope (ZEISS, Oberkochen, Germany).

Western blot assay {#sec2-4}
------------------

After the rats were anesthetized with 8% chloral hydrate via intraperitoneal injection and killed, their brains were harvested. The substantia nigra was separated and weighed in the Eppendorf tube, then the tissue was ground using 100 µL of 4 mg lysis buffer and centrifuged for 30 minutes at 14,000 × *g* at 4°C. The supernatant was collected and denatured with 4× loading buffer for 5 minutes at 95 °C. Forty µg total protein was used for protein electrophoresis and transferred onto membranes. The membranes were blocked for 2 hours and incubated with mouse anti-rat TH monoclonal antibody (1:2,000; Sigma) and mouse anti-rat PSPN monoclonal antibody (1:200; Invitrogen, Karlsruhe, Germany) at 4°C overnight. After three washes in TBST, samples were incubated with donkey anti-mouse IgG (1:2,000; Abcam, Cambridge, MA, USA) for 1 hour. Immunoreactivity was visualized using ECL western blot assay and optical density was analyzed using a UVP Image System (Upland, CA, USA).

High-performance liquid chromatography (HPLC) {#sec2-5}
---------------------------------------------

At 8 weeks post-transplantation, striatal concentrations of DA, Dihydroxy phenyl acetic acid (DOPAC) and homovanillic acid (HVA) were measured by HPLC with an electrochemical detector (ZEISS). Rats were decapitated at 4°C under sterile conditions. The brain tissue was rinsed with ice-cold PBS, precisely weighed, and homogenized in an ice-cold perchloric acid and EDTA solution (0.4 M HClO~4~, 0.5 mM Na2-EDTA, 0.01% L-cysteine) to yield a 10% (w/v) homogenate at 0 °C. The homogenates were centrifuged at 14,000 × *g* at 4°C for 15 minutes. After centrifugation, the supernatants were removed, and 0.5 volume of potassium salt solution (20 mmol/L potassium citrate, 300 mmol/L KH~2~PO~4~, 2 mmol/L Na2-EDTA) was added at 0°C for 15 minutes. The precipitates were then centrifuged at 14,000 × *g* at 0--4°C for 15 minutes. After centrifugation, the supernatants were frozen at --80°C or immediately applied to the HPLC system (ZEISS). Dialysis samples were assayed for DA, DOPAC and HVA by HPLC with electrochemical detection. The samples were placed in the 717 Plus Autosampler (Waters, Milford, MA, USA) connected to the 2465ECD (Waters) equipped with a C18 reverse-phase column (4.6 × 75 mm, 3.5 µm; Waters). The samples were eluted by mobile phase (100 mM Na-citrate, 0.1 mM EDTA, 75 mM Na~2~HPO~4~, 2 mM NaCl, 1 mM C-7 at pH 3.9, 10% methanol) at a flow rate of 0.6 mL/min. DA, DOPAC and HVA levels were calculated by extrapolating the peak area from a standard curve (ranging from 1 nM to 100 nM of mixed DA, DOPAC and HVA). The identification of peaks was carried out by comparison with standards. The amounts of DA in each sample were quantified by comparing the peak area of the samples with those of the standards.

Statistical analysis {#sec2-6}
--------------------

Statistical analysis was conducted using GraphPad Prism 6.0 software (GraphPad Software Inc., LaJolla, CA, USA). The data are expressed as the mean ± SD and analyzed by one-way or two-way analysis of variance. Statistical significance was determined as *P* \< 0.05.

Results {#sec1-3}
=======

LV-PSPN over-expressed PSPN in dopaminergic neurons {#sec2-7}
---------------------------------------------------

Seventy-two hours after dopaminergic neurons were transfected with LV-PSPN, 95% of green fluorescent protein (GFP)-positive dopaminergic neurons were observed. Western blot assay results showed that dopaminergic neurons expressed endogenous PSPN and that LV-null infection did not affect the expression of PSPN, whereas LV-PSPN significantly induced high expression of PSPN ([**Figure 1A**](#F1){ref-type="fig"}). Immunofluorescence staining showed that dopaminergic neurons mostly expressed the TH and PSPN ([**Figure 1B**](#F1){ref-type="fig"}). Therefore, LV-PSPN could effectively infect dopaminergic neurons and increase the protein expression of PSPN.

![Lentivirus-mediated Persephin (LV-PSPN) over-expressed PSPN in dopaminergic neurons of rat substantia nigra.\
(A) Dopaminergic neurons expressed the PSPN and TH effectively (immunofluorescence staining). Scale bars: 100 mm. (B, C) PSPN expression in dopaminergic neurons transfected with LV-PSPN (western blot assay). β-Actin was used as a loading control. Data are expressed as the mean ± SD and were analyzed by one-way analysis of variance. There were 10 rats in each group. TH: Tyrosine hydroxylase; 6-OHDA: 6-hydroxydopamine.](NRR-10-1814-g001){#F1}

Neuroprotection by PSPN on 6-OHDA-lesioned dopaminergic neurons {#sec2-8}
---------------------------------------------------------------

Rats in the 6-OHDA group and 6-OHDA + LV-null group had about 15% residual substantia nigra TH cells, which was significantly lower than the normal group (*P* \< 0.05); rats in the 6-OHDA + LV-PSPN group had approximately 50% residual substantia nigra TH cells, which was higher than the 6-OHDA group and the 6-OHDA + LV-null group (*P* \< 0.05; [**Figure 2**](#F2){ref-type="fig"}).

![PSPN increased TH expression in dopaminergic neurons of rat substantia nigra.\
(A) Effect of PSPN on TH expression in dopaminergic neurons (western blot assay). Western blotting films from three independent experiments were scanned and the relative density of protein bands was calculated using β-actin as a loading control. (B) Immunofluorescence staining of TH in the nigra. Fluorescent staining agent was DyLight 488. Scale bars: 100 mm. Data are expressed as the mean ± SD and were analyzed by one-way analysis of variance. There were 10 rats in each group. \**P* \< 0.05, *vs*. normal group; \#*P* \< 0.05, *vs*. 6-OHDA + LV-null group or 6-OHDA group. LVPSPN: Lentivirus-mediated Persephin; TH: tyrosine hydroxylase; 6-OHDA: 6-hydroxydopamine.](NRR-10-1814-g002){#F2}

Transplantation of LV-PSPN-transfected neural stem cells increased the striatal dopamine expression in 6-OHDA-induced injury rats {#sec2-9}
---------------------------------------------------------------------------------------------------------------------------------

Dopamine levels in the striatum were determined by HPLC. Mean dopamine level in the striatum of rats in the 6-OHDA group and 6-OHDA + LV-null group was lower than that of the normal group (*P* \< 0.05). Dopamine level in the striatum of rats showed no significant difference between the 6-OHDA group and 6-OHDA + LV-null group (*P* \> 0.05). After pretreatment with LV-PSPN, the dopamine level was increased by 179% compared with the two other groups (*P* \< 0.05; [**Figure 3**](#F3){ref-type="fig"}).

![The levels of dopamine (DA), 3-4-dihydroxy-phenylacetic acid (DOPAC) and homovanillic acid (HVA) in Parkinson\'s disease rats after transfection.\
Data are expressed as the mean ± SD and were analyzed by two-way analysis of variance. There were 10 rats in each group. \**P* \< 0.05, *vs*. normal group; \#*P* \< 0.05, *vs*. 6-OHDA + LV-null group or 6-OHDA group. LV-PSPN: Lentivirus-mediated Persephin; 6-OHDA: 6-hydroxydopamine.](NRR-10-1814-g003){#F3}

Transplantation of LV-PSPN-transfected neural stem cells improved the behavior of 6-OHDA-induced injury rats {#sec2-10}
------------------------------------------------------------------------------------------------------------

The apomorphine-induced rotational behaviors of rats in all groups are shown in [**Figure 4**](#F4){ref-type="fig"}. The average rotational rate of the normal group hardly changed from the baseline (0 rotation/30 minutes). In contrast, the rotational rates of rats in the 6-OHDA + LV-null group and the 6-OHDA group averaged more than 300 rotations per 30 minutes, significantly greater than before treatment (*P* \< 0.05). The average rotational rates of rats implanted with 6-OHDA + LV-PSPN were half those in the other two 6-OHDA groups (*P* \< 0.05).

![The apomorphine-induced rotational behaviors of 6-OHDA-induced Parkinson\'s disease rats after transplantation of LV-PSPN-transfected neural stem cells.\
Data are expressed as the mean ± SD and were analyzed by two-way analysis of variance. There were 10 rats in each group. \**P* \< 0.05, *vs*. normal group; \#*P* \< 0.05, *vs*. 6-OHDA + LV-null group or 6-OHDA group. LV-PSPN: Lentivirus-mediated Persephin; 6-OHDA: 6-hydroxydopamine.](NRR-10-1814-g004){#F4}

Discussion {#sec1-4}
==========

Neurotrophic factors have been demonstrated to exert potent effects on neurons, such as the promotion of survival, neurite branching, synaptogenesis, modulation of electrophysiological properties and synaptic plasticity (Kuhlmann et al., 2006; Wang et al., 2013; Zhang et al., 2014). GDNF, a distantly related member of the transforming growth factor-beta superfamily and a potent neurotrophic factor, can affect neuronal differentiation, development, growth and survival in the central nervous system and has neuroprotective effects against a variety of neuronal insults (Conover et al., 1993; Tang et al., 2014). However, the effects of GDNF are transient, and need repeated administration into brain parenchyma or intraventricular space (Parker et al., 2014). In addition, as a large protein, GDNF has difficulty in crossing the blood-brain barrier (Barichello et al., 2014). This limits the clinical application of GDNF. Direct intravenous administration of a clinical applicable gene in rats subjected to middle cerebral artery occlusion increased clinical applicability levels, reduced infarct volume at the affected hemisphere, and improved behavioral performance (Bensadoun et al., 2000). Moreover, transplantation of GDNF gene-modified stem cells promotes differentiation into neurofilament-positive cells and has better therapeutic effects in intracerebral hemorrhage models in rats than the transplantation of empty virus-transfected stem cells (DeWitt et al., 2014; Du et al., 2014). Therefore, GDNF may have some therapeutic potential for central nervous system diseases.

In the past decade, gene therapy has painted the prospect of better PD treatments (Arimura et al., 2014). If the genes of neuroprotective factors are delivered to the striatum, the progressive loss of dopaminergic neurons should be interrupted. PSPN, a recently cloned member of the transforming growth factor-β superfamily and GDNF subfamily, is distributed throughout the nervous system at extremely low levels. Therefore, we used PSPN as the therapeutic gene to provide a protective effect against progressive degeneration of dopaminergic neurons.

The findings of this study show a promising application of PSPN in gene therapy to treat PD. In this study, we observed that PSPN could prevent the severe reduction in dopaminergic cell count in substantia nigra and striatal dopamine content in the striatum caused by 6-OHDA treatment. This study also indicates that intracellular transduction of the PSPN gene can reduce the rotational behavior in a rat model of PD to some extent. This indicates that PSPN can directly protect nigra dopaminergic neurons against the toxicity of 6-OHDA by countering its effects.
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